Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 3, 2012
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is...
-
Dec 19, 2011Novato, CA Expansion Doubles Current Capacity to Support up to a Billion Dollars in Revenue
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for the...
-
Dec 8, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today hosted a Research and Development Day where members of the company's management team and industry experts provided an update on BioMarin's product...
-
Nov 30, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a unit of the Central Adelaide Local Health...
-
Nov 29, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with...
-
Nov 28, 2011Novato, CA Expansion Doubles Current Capacity to Support up to a Billion Dollars in Revenue
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the manufacturing facility expansion in Novato, CA....
-
Nov 17, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Thursday, December 8, 2011 from 8:00 a.m. to 12:00 p.m. at the Four Seasons...
-
Nov 3, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Credit Suisse Healthcare...
-
Oct 27, 2011Pipeline to be Highlighted at R&D Day on December 8th; Many Key Clinical Milestones in the Coming Year
Financial Highlights ($ in millions, except per share data, unaudited) Item Q3 2011 Q3 2010 Comparison Total BioMarin Revenue $113.4 16.0% increase Total Net Product Revenue $112.9 16.9% increase...
-
Sep 29, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 27, at...
-
Sep 20, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Jefferies Global Healthcare...
-
Sep 13, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the UBS Global Life Sciences Conference in New...
-
Sep 7, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare...
-
Aug 30, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Baird Health Care Conference in New York...
-
Aug 9, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference...
-
Jul 28, 2011Ongoing study suggests GALNS sustains improvements in endurance and respiratory function for at least 2 years
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced an update on the GALNS Phase 1/2 extension study (MOR-100) in which patients have continued treatment on an ongoing basis. Patients...
-
Jul 28, 2011Strong Commercial Performance Drives 20% Year Over Year Growth in Total Revenue Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited) Item Q2 2011 Q2 2010 Comparison Total BioMarin Revenue $110.6 20.2% increase Total Net Product Revenue $109.6 21.0% increase...
-
Jul 14, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with...
-
Jun 30, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 28, at 5:00...
-
Jun 23, 2011New facility will greatly expand manufacturing capacity and diversify risk
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has entered into a definitive agreement to acquire a bulk biologics manufacturing plant from Pfizer, located in Shanbally, Cork,...
-
Jun 8, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the William Blair Growth...
-
Jun 7, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first patient has been dosed in the Phase 3 trial for amifampridine phosphate (3,4-diaminopyridine phosphate) for the treatment...
-
May 31, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Jefferies Global Healthcare Conference in...
-
May 18, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the UBS Global Specialty...
-
May 3, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Merrill Lynch...
-
Apr 28, 2011Net Product Revenue Growth of 30% in the First Quarter of 2011; Improved Top and Bottom-Line Guidance
Financial Highlights ($ in millions, except per share data, unaudited) Item Q1 2011 Q1 2010 Comparison Total BioMarin Revenue $109.5 28.8% increase Total Net Product Revenue $109.1 29.7% increase...
-
Apr 26, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank Healthcare Conference in...
-
Mar 28, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28, at 5:00...
-
Mar 18, 2011Additional posters at ACMG describe ongoing studies designed to further examine the use of KUVAN® for PKU, with endpoints of neuropsychiatric effects and long-term safety in children
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in...
-
Mar 8, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Barclays Global Healthcare...
-
Mar 1, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Cowen Health Care...
-
Feb 22, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Citi Global...
-
Feb 17, 2011Net Product Revenue Growth of 17% in 2010; Late Stage Clinical Pipeline Advancing
Financial Highlights ($ in millions, except per share data, unaudited) Item FY 2010 FY 2009 Comparison Total BioMarin Revenue $376.3 15.9% increase Total Net Product Revenue $369.7 17.1% increase...
-
Feb 1, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of...
-
Jan 24, 2011Conference Call and Webcast on Thursday, February 17 at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 17, at...
-
Jan 19, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase...
-
Jan 11, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development for the treatment of...
-
Jan 5, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan 29th Annual Healthcare...
-
Dec 14, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application...
-
Dec 7, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Deutsche Bank...
-
Dec 2, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application...
-
Nov 29, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in...
-
Nov 9, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that six holders of its 2.50% Convertible Senior Subordinated Notes due 2013 have agreed to exchange $87.0 million in aggregate...
-
Oct 28, 2010Strong Performance in Commercial Business; Best Quarter Ever for Net Product Revenue
Financial Highlights ($ in millions, except per share data, unaudited) Item Q3 2010 Q3 2009 Comparison Total BioMarin Revenue $97.8 21.0% increase Total Net Product Revenue $96.6 23.2% increase...
-
Oct 19, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter...
-
Oct 14, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel...
-
Oct 7, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28, at...
-
Oct 5, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel...
-
Sep 23, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors. "We are extremely pleased to welcome William Young...
-
Sep 14, 2010
BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President, Corporate and Business Development of BioMarin, will present a company update at the UBS Global Life Sciences...